Matinas BioPharma Stock Price, News & Analysis (NYSEAMERICAN:MTNB)

$1.50 0.11 (7.91 %)
(As of 12/11/2017 04:00 PM ET)
Previous Close$1.39
Today's Range$1.38 - $1.50
52-Week Range$1.01 - $3.99
Volume211,100 shs
Average Volume339,877 shs
Market Capitalization$139.43 million
P/E RatioN/A
Dividend YieldN/A
Beta0.7

About Matinas BioPharma (NYSEAMERICAN:MTNB)

Matinas BioPharma logoMatinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Its cochleate delivery technology platform is designed for the targeted delivery of pharmaceuticals directly to the site of infection or inflammation. Its MAT 2203 is an oral formulation of a spectrum anti-fungal drug called amphotericin B, which uses its cochleate delivery technology. Its MAT2501 is an orally administered, encochleated formulation of the spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including non-tubercular mycobacterial infections (NTM), as well as various multidrug-resistant gram negative and intracellular bacterial infections.

Receive MTNB News and Ratings via Email

Sign-up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNYSEAMERICAN:MTNB
CUSIPN/A
Phone+1-908-4431860

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.37)
Net IncomeN/A
Net Margins-7,558.92%
Return on Equity-195.09%
Return on Assets-79.34%

Miscellaneous

EmployeesN/A
Outstanding Shares92,950,000

Matinas BioPharma (NYSEAMERICAN:MTNB) Frequently Asked Questions

What is Matinas BioPharma's stock symbol?

Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."

How were Matinas BioPharma's earnings last quarter?

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) released its quarterly earnings data on Wednesday, November, 15th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01. The company had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.05 million. Matinas BioPharma had a negative return on equity of 195.09% and a negative net margin of 7,558.92%. View Matinas BioPharma's Earnings History.

Where is Matinas BioPharma's stock going? Where will Matinas BioPharma's stock price be in 2017?

3 brokerages have issued 12 month target prices for Matinas BioPharma's stock. Their forecasts range from $6.00 to $9.00. On average, they expect Matinas BioPharma's share price to reach $7.67 in the next year. View Analyst Ratings for Matinas BioPharma.

What are Wall Street analysts saying about Matinas BioPharma stock?

Here are some recent quotes from research analysts about Matinas BioPharma stock:

  • 1. Maxim Group analysts commented, "Summary Matinas stock is down sharply today on news that MAT2203’s efficacy in VVC (vulvovaginal candidiasis) fell well below expectations both internal and external, but wait a second…Was it ever supposed to compare?." (6/26/2017)
  • 2. Aegis analysts commented, "Matinas reported the results of the Phase I study testing safety, tolerability and pharmacokinetics of MAT2501, its cochleated version of amikacin. This announcement meets the endpoints and time frame we had expected. Separately, we have received inquiries regarding comments posted to a financial website to which we attribute the recent volatility in the stock. We believe these comments are based on incorrect information, and reiterate our Buy rating on the stock." (3/28/2017)

Are investors shorting Matinas BioPharma?

Matinas BioPharma saw a decrease in short interest in November. As of November 15th, there was short interest totalling 1,998,494 shares, a decrease of 2.8% from the October 31st total of 2,055,677 shares. Based on an average daily trading volume, of 91,408 shares, the days-to-cover ratio is presently 21.9 days. Approximately 2.8% of the company's shares are short sold.

Who are some of Matinas BioPharma's key competitors?

Who are Matinas BioPharma's key executives?

Matinas BioPharma's management team includes the folowing people:

  • Jerome D. Jabbour J.D., President (Age 42)
  • Roelof Rongen, Chief Executive Officer, Director (Age 51)
  • Gary Gaglione CPA, Vice President of Finance and Accounting and Acting Chief Financial Officer (Age 64)
  • Douglas F. Kling, Senior Vice President - Clinical Development (Age 43)
  • Abdel A. Fawzy Ph.D., Executive Vice President for Pharmaceutical and Supply Chain Development (Age 66)
  • Dominick M. Dipaolo, Senior Vice President - Quality and Regulatory Compliance (Age 41)
  • Raphael J. Mannino Ph.D., Chief Scientific Officer (Age 70)
  • Herbert J. Conrad, Chairman of the Board (Age 84)
  • Eric J. Ende M.D., Director (Age 48)
  • Adam K. Stern, Director (Age 53)

Who owns Matinas BioPharma stock?

Matinas BioPharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Yellowstone Partners LLC (0.16%). Company insiders that own Matinas BioPharma stock include Adam K Stern, James S Scibetta and Roelof Rongen. View Institutional Ownership Trends for Matinas BioPharma.

Who bought Matinas BioPharma stock? Who is buying Matinas BioPharma stock?

Matinas BioPharma's stock was purchased by a variety of institutional investors in the last quarter, including Yellowstone Partners LLC. Company insiders that have bought Matinas BioPharma stock in the last two years include Adam K Stern, James S Scibetta and Roelof Rongen. View Insider Buying and Selling for Matinas BioPharma.

How do I buy Matinas BioPharma stock?

Shares of Matinas BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Matinas BioPharma's stock price today?

One share of Matinas BioPharma stock can currently be purchased for approximately $1.50.

How big of a company is Matinas BioPharma?

Matinas BioPharma has a market capitalization of $139.43 million.

How can I contact Matinas BioPharma?

Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860.


MarketBeat Community Rating for Matinas BioPharma (MTNB)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  74 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  117
MarketBeat's community ratings are surveys of what our community members think about Matinas BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Matinas BioPharma (NYSEAMERICAN:MTNB) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.67$7.67$7.67$7.00
Price Target Upside: 463.73% upside463.73% upside463.73% upside190.46% upside

Matinas BioPharma (NYSEAMERICAN:MTNB) Consensus Price Target History

Price Target History for Matinas BioPharma (NYSEAMERICAN:MTNB)

Matinas BioPharma (NYSEAMERICAN:MTNB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
8/10/2017Roth CapitalSet Price TargetBuy$9.00View Rating Details
8/8/2017Maxim GroupSet Price TargetBuy$6.00View Rating Details
3/28/2017AegisReiterated RatingBuy -> Positive$8.00View Rating Details
(Data available from 12/11/2015 forward)

Earnings

Matinas BioPharma (NYSEAMERICAN:MTNB) Earnings History and Estimates Chart

Earnings by Quarter for Matinas BioPharma (NYSEAMERICAN:MTNB)

Matinas BioPharma (NYSEAMERICAN MTNB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/15/2017Q3 2017($0.05)($0.04)$0.05 million$0.05 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.05)($0.04)$0.02 million$0.05 millionViewListenView Earnings Details
5/16/2017Q1 2017($0.04)($0.25)$0.02 millionViewN/AView Earnings Details
4/3/2017Q4 2016($0.08)($0.03)ViewListenView Earnings Details
11/10/2015Q3 2016($0.03)($0.11)$0.10 million$0.06 millionViewN/AView Earnings Details
8/13/2015Q2 2015($0.05)($0.04)$0.10 million$0.08 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Matinas BioPharma (NYSEAMERICAN:MTNB) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Matinas BioPharma (NYSEAMERICAN:MTNB)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Matinas BioPharma (NYSEAMERICAN MTNB) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Matinas BioPharma (NYSEAMERICAN:MTNB)

Matinas BioPharma (NYSEAMERICAN MTNB) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/8/2017Adam K SternDirectorBuy100,000$1.38$138,000.00View SEC Filing  
9/8/2017Roelof RongenCEOBuy5,000$1.36$6,800.00View SEC Filing  
9/7/2017James S ScibettaDirectorBuy5,000$1.29$6,450.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Matinas BioPharma (NYSEAMERICAN MTNB) News Headlines

Source:

SEC Filings

Matinas BioPharma (NYSEAMERICAN:MTNB) SEC Filings

DateFilerForm TypeView

Social Media

Financials

Financials are not available for this stock.

Chart

Matinas BioPharma (NYSEAMERICAN MTNB) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.